Drug Type Small molecule drug |
Synonyms EX 597, EX-597, EX597 + [2] |
Target |
Action inhibitors |
Mechanism FAAH2 inhibitors(Fatty-acid amide hydrolase 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC20H22N2O3 |
InChIKeyROFVXGGUISEHAM-UHFFFAOYSA-N |
CAS Registry546141-08-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | URB-597 | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Schizophrenia | Phase 1 | Germany | 31 Jan 2025 | |
Autism Spectrum Disorder | Preclinical | United States | 01 Apr 2025 | |
Phobia, Social | Preclinical | Canada | 16 Jul 2024 | |
Stress Disorders, Post-Traumatic | Preclinical | Canada | 16 Jul 2024 |